
Nancy K Gillis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6101738/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	9.4	367
2	Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncology, The, 2017, 18, 112-121.	5.1	249
3	Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. Clinical Cancer Research, 2018, 24, 5918-5924.	3.2	84
4	Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist, 2017, 22, 144-151.	1.9	74
5	Higher genetic diversity in introduced than in native populations of the mussel <i>Mytella charruana</i> : evidence of population admixture at introduction sites. Diversity and Distributions, 2009, 15, 784-795.	1.9	66
6	Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next-Generation Sequencing Era. Clinical Pharmacology and Therapeutics, 2014, 95, 269-280.	2.3	62
7	Managing Clonal Hematopoiesis in Patients With Solid Tumors. Journal of Clinical Oncology, 2019, 37, 7-11.	0.8	60
8	Evidence Required to Demonstrate Clinical Utility of Pharmacogenetic Testing: The Debate Continues. Clinical Pharmacology and Therapeutics, 2014, 96, 655-657.	2.3	42
9	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discovery, 2022, 3, 385-393.	2.6	29
10	The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resistance Updates, 2016, 28, 28-42.	6.5	24
11	Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis inÂaÂLarge Cancer Patient Cohort. Journal of Investigative Dermatology, 2017, 137, 2021-2023.	0.3	18
12	Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Advances, 2022, 6, 3767-3778.	2.5	13
13	Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. PLoS ONE, 2013, 8, e76984.	1.1	11
14	Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off‣abel Drug Use. Pharmacotherapy, 2017, 37, 1043-1051.	1.2	6
15	Cancer and aging: A call to action. Aging and Cancer, 2022, 3, 87-94.	0.5	5
16	An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. Neuropsychiatric Disease and Treatment, 2011, 7, 501.	1.0	3
17	Chipping in on clonal hematopoiesis. Oncotarget, 2017, 8, 84637-84638.	0.8	1
18	Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. Oncotarget, 2017, 8, 115114-115127.	0.8	1

NANCY K GILLIS

#	Article	IF	CITATIONS
19	Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays Journal of Clinical Oncology, 2018, 36, 12068-12068.	0.8	1
20	Pharmacogenetic Evaluation of Targeted Dna Sequencing in Cancer Patients. Annals of Oncology, 2014, 25, iv558.	0.6	0
21	Somatic Sequencing Identifies Trametinib-Responsive Myelodysplastic Syndrome and Finds Acquired Clonal Hematopoiesis of Indeterminate Potential. JCO Precision Oncology, 2018, 2, 0-0.	1.5	0
22	Abstract 4304: Prevalence and triggers of drug-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in a cancer patient cohort. , 2016, , .		0
23	Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly. Blood, 2016, 128, 295-295.	0.6	0
24	Hematopoiesis and Aging. , 2018, , 1-24.		0
25	Hematopoiesis and Aging. , 2020, , 305-328.		0
26	COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study. Blood, 2021, 138, 2611-2611.	0.6	0
27	Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma. Blood, 2021, 138, 402-402.	0.6	0
28	A Pilot Study Exploring the Link between Donor-Engrafted Clonal Hematopoiesis and Outcomes of Allogeneic Hematopoietic Cell Transplantation from Older Matched Sibling Donors. Transplantation and Cellular Therapy, 2022, 28, S306-S307.	0.6	0